QC
ADCT icon

Quadrature Capital’s ADC Therapeutics ADCT Stock Holding History

Quadrature Capital’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$113K Buy
+105,690
New +$308K ﹤0.01% 1452

Other funds holding ADCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SCTC
Sanibel Captiva Trust Company Sanibel, Florida $4.02B AUM 34.36% 1-Year Est. Return
RWP
Revolve Wealth Partners Hackensack, New Jersey $965M AUM 22.88% 1-Year Est. Return
WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.48B AUM 24.77% 1-Year Est. Return
DIM
DLK Investment Management Solana Beach, California $235M AUM 12.41% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Quadrature Capital's ADCT Position: Q2 2026 in Review

Quadrature Capital opened a new position in ADC Therapeutics (ADCT) in Q2 2026: 105,690 shares worth $113K. The stake represents ﹤0.01% of the portfolio and ranks #1452 among its holdings.

38 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Quadrature Capital held 105,690 shares of ADC Therapeutics worth $113K as of Q2 2026.
  • ADC Therapeutics was a new Quadrature Capital position in Q2 2026.
  • ADC Therapeutics made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1452 holding.
  • 38 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.